Adjuvant Therapy in Early UterineSerousCarcinoma. Uterineserouscarcinoma (USC) is a rare diagnosis but associated with high mortality. There is limited data to guide adjuvant treatment decisions in early stage disease. The purpose of this study is to evaluate the impact of adjuvant therapy on recurrence-free survival (RFS) and overall survival (OS) in early stage USC. Patients with stage I
A retrospective study evaluating the effect of trastuzumab addition to carboplatin/paclitaxel on overall survival in patients with advanced-stage HER2/neu-overexpressing uterineserouscarcinoma or carcinosarcoma. Uterineserouscarcinoma and carcinosarcoma are aggressive forms of endometrial cancer with poor survival outcomes. Trastuzumab, a human epidermal growth factor receptor-2 (HER2 )-directed monoclonal antibody, has demonstrated tumoricidal efficacy. However, clinical data regarding its efficacy in uterineserouscarcinoma are limited, and there are no clinical data available for uterine carcinosarcoma. Therefore, this study aimed to ascertain the efficacy and safety of adding trastuzumab to carboplatin and paclitaxel as a frontline treatment for advanced-stage HER2-overexpressing
Loss of GATA2 Promotes Invasion and Predicts Cancer Recurrence and Survival in UterineSerousCarcinoma. A priori knowledge of recurrence risk in patients with non-metastatic (FIGO stage I) uterineserouscarcinoma (USC) would enable a risk-stratified approach to the use of adjuvant chemotherapy. This would greatly reduce treatment-related morbidity and be predicted to improve survival. GATA2
High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterineserouscarcinoma cell lines. Uterineserouscarcinoma is a highly aggressive non-endometrioid subtype of endometrial cancer with poor survival rates overall, creating a strong need for new therapeutic strategies to improve outcomes. High-dose ascorbate (vitamin C) has been shown to inhibit cell proliferation and tumor growth in multiple preclinical models and has shown promising anti-tumor activity in combination with chemotherapy, with a favorable safety profile. We aimed to study the anti-tumor effects of ascorbate and its synergistic effect with carboplatin on uterineserouscarcinoma cells. Cell proliferation was evaluated by MTT
The comparison of pure uterineserouscarcinoma and mixed tumor with serous component: a single-institution review of 91 cases. Pure uterineserouscarcinoma (p-USC) and mixed tumors with serous component (m-USC) are aggressive subtypes of endometrial cancer associated with high mortality rates. This retrospective study aimed to compare clinicopathologic features and outcomes of p-USC and m-USC
Targeting Galectin 3 illuminates its contributions to the pathology of uterineserouscarcinoma. Uterine serous cancer (USC) comprises around 10% of all uterine cancers. However, USC accounts for approximately 40% of uterine cancer deaths, which is attributed to tumor aggressiveness and limited effective treatment. Galectin 3 (Gal3) has been implicated in promoting aggressive features in some
Laparoscopy with or without robotic assistance does not negatively impact long-term oncologic outcomes in patients with uterineserouscarcinoma. We sought to compare outcomes between minimally invasive surgery (MIS) and laparotomy in patients with clinical stage I uterineserouscarcinoma (USC). Patients who underwent surgery for newly diagnosed USC between 11/1/1993 and 12/31/2017 were
HER2 in UterineSerousCarcinoma: Testing platforms and implications for targeted therapy. HER2 is an important prognostic and therapeutic target in uterineserouscarcinoma (USC). Optimal HER2 testing platforms have not been defined and guidelines for testing have changed over time. Our objective is to assess the concordance of HER2 positivity based on chromogenic in situ hybridization (CISH
Uterineserouscarcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center. To evaluate factors impacting survival outcomes in patients with uterineserouscarcinoma (USC). Data of consecutive patients diagnosed with USC undergoing surgery between 2000 and 2020 at Fondazione IRCCS Istituto Nazionale Tumori of Milan (Italy) were reviewed. Progression-free (PFS
Synergistic activity of neratinib in combination with olaparib in uterineserouscarcinoma overexpressing HER2/neu. Uterineserouscarcinoma (USC) is an aggressive variant of endometrial cancer with a poor prognosis. Approximately 30% of USC overexpress HER2/neu, a recognized target for trastuzumab in advanced/recurrent HER2/neu-positive USC. We evaluated the efficacy of the pan-c-erb inhibitor
Adjuvant therapy in women with early stage uterineserouscarcinoma: A multi-institutional study. Uterineserouscarcinoma is a rare but aggressive subtype of endometrial adenocarcinoma. Our objective was to compare adjuvant treatment strategies for patients with early stage uterineserouscarcinoma. This multi-institutional, retrospective cohort study evaluated patients with early stage uterine with and without chemotherapy was associated with improved survival outcomes in patients with early stage uterineserouscarcinoma.
A Durable Response to Pembrolizumab in a Patient with UterineSerousCarcinoma and Lynch Syndrome due to the MSH6 Germline Mutation. Pembrolizumab, a programmed death 1 ligand (PD-1) checkpoint inhibitor, has elicited responses in mismatch repair (MMR)-deficient advanced solid tumors, leading to its agnostic approval by the US Food and Drug Administration in 2017 when no other therapeutic options are available. However, there are still insufficient data on the response to checkpoint inhibitors in advanced endometrial cancer related to Lynch syndrome (LS) and, specifically, in uterineserouscarcinoma, which is uncommon in LS. Here we report a case of metastatic uterineserouscarcinoma due to a germline MSH6 mutation (Lynch syndrome) that was discovered because of a patient's tumor MMR deficiency
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterineserouscarcinomas that overexpress HER2/neu. Due to previously reported trastuzumab safety concerns and the scant data available in endometrial cancer patients, we sought to assess the safety, tolerability and toxicity profile of trastuzumab in patients with advanced/recurrent uterineserouscarcinoma (USC
Human epidermal growth factor 2 (HER2) in early stage uterineserouscarcinoma: A multi-institutional cohort study. Human epidermal growth factor receptor 2 (HER2) has emerged as an important prognostic and therapeutic target in advanced stage and recurrent uterineserouscarcinoma (USC). The significance of tumoral HER2 expression in early-stage disease has not been established. This multi association with worse recurrence and survival outcomes, HER2 positivity appears to be a prognostic biomarker in women with stage I uterineserouscarcinoma. These data provide support for clinical trials with anti-HER2-directed therapy in early-stage disease.
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent UterineSerousCarcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis of preliminary results of a multicenter, randomized phase II
Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterineserouscarcinoma. To compare the frequencies of somatic homologous recombination (HR) gene mutations identified in next-generation sequencing (NGS) genomic profiling of uterineserouscarcinomas (USCs
A 73-gene proliferative transcriptomic signature predicts uterineserouscarcinoma patient survival and response to primary therapy. To develop a transcriptomic signature capable of predicting overall survival (OS) for uterineserouscarcinoma (USC). RNAseq data for 58 USC patients were obtained from TCGA. Expression of 73 candidate genes was measured for 67 Augusta University (AU) samples using
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterineserouscarcinoma. Uterineserouscarcinoma (USC) is an aggressive variant of endometrial cancer with poor prognosis. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast cell-surface antigen 2 (Trop-2
Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterineserouscarcinoma. The objective of our study was to assess survival among patients with uterineserouscarcinoma (USC) undergoing sentinel lymph node (SLN) mapping alone versus patients undergoing systematic lymphadenectomy (LND). We retrospectively reviewed patients undergoing primary surgical
Fallopian tube abnormalities in uterineserouscarcinoma. Uterineserouscarcinoma (USC) is presumed to arise from endometrial intra-epithelial carcinoma (EIC), whereas tubo-ovarian high-grade serous carcinomas have similar precursor lesions in the Fallopian tube, i.e. serous tubal intra-epithelial carcinoma (STIC). The presence of Fallopian tube abnormalities and their clonal relationship